This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perni, R. B.
Right arrow Articles by Lin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perni, R. B.
Right arrow Articles by Lin, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 899-909, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.899-909.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

Robert B. Perni,* Susan J. Almquist, Randal A. Byrn, Gurudatt Chandorkar, Pravin R. Chaturvedi, Lawrence F. Courtney, Caroline J. Decker, Kirk Dinehart, Cynthia A. Gates, Scott L. Harbeson, Angela Heiser, Gururaj Kalkeri, Elaine Kolaczkowski, Kai Lin, Yu-Ping Luong, B. Govinda Rao, William P. Taylor, John A. Thomson, Roger D. Tung, Yunyi Wei, Ann D. Kwong, and Chao Lin*

Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139

Received 8 August 2005/ Returned for modification 4 October 2005/ Accepted 8 December 2005

VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC50] = 354 nM) and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera (IC50 = 280 nM). VX-950 forms a covalent but reversible complex with the genotype 1a HCV NS3-4A protease in a slow-on, slow-off process with a steady-state inhibition constant (Ki*) of 7 nM. Dissociation of the covalent enzyme-inhibitor complex of VX-950 and genotype 1a HCV protease has a half-life of almost an hour. A >4-log10 reduction in the HCV RNA levels was observed after a 2-week incubation of replicon cells with VX-950, with no rebound of viral RNA observed after withdrawal of the inhibitor. In several animal species, VX-950 exhibits a favorable pharmacokinetic profile with high exposure in the liver. In a recently developed HCV protease mouse model, VX-950 showed excellent inhibition of HCV NS3-4A protease activity in the liver. Therefore, the overall preclinical profile of VX-950 supports its candidacy as a novel oral therapy against hepatitis C.

* Corresponding author. Mailing address: Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139. Phone for Robert B. Perni: (617) 444-6237. Fax: (617) 444-6766. E-mail: robert_perni{at}vrtx.com. Phone for Chao Lin: (617) 444-6202. Fax: (617) 444-6210. E-mail: chao_lin{at}vrtx.com.

Antimicrobial Agents and Chemotherapy, March 2006, p. 899-909, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.899-909.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourliere, M., Gharakhanian, S., Bengtsson, L., McNair, L., George, S., Kieffer, T., Kwong, A., Kauffman, R. S., Alam, J., Pawlotsky, J.-M., Zeuzem, S., the PROVE2 Study Team, (2009). Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. NEJM 360: 1839-1850 [Abstract] [Full Text]  
  • Coelmont, L., Kaptein, S., Paeshuyse, J., Vliegen, I., Dumont, J.-M., Vuagniaux, G., Neyts, J. (2009). Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors. Antimicrob. Agents Chemother. 53: 967-976 [Abstract] [Full Text]  
  • Sabariegos, R., Picazo, F., Domingo, B., Franco, S., Martinez, M.-A., Llopis, J. (2009). Fluorescence Resonance Energy Transfer-Based Assay for Characterization of Hepatitis C Virus NS3-4A Protease Activity in Live Cells. Antimicrob. Agents Chemother. 53: 728-734 [Abstract] [Full Text]  
  • Seiwert, S. D., Andrews, S. W., Jiang, Y., Serebryany, V., Tan, H., Kossen, K., Rajagopalan, P. T. R., Misialek, S., Stevens, S. K., Stoycheva, A., Hong, J., Lim, S. R., Qin, X., Rieger, R., Condroski, K. R., Zhang, H., Do, M. G., Lemieux, C., Hingorani, G. P., Hartley, D. P., Josey, J. A., Pan, L., Beigelman, L., Blatt, L. M. (2008). Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52: 4432-4441 [Abstract] [Full Text]  
  • Howe, A. Y. M., Cheng, H., Johann, S., Mullen, S., Chunduru, S. K., Young, D. C., Bard, J., Chopra, R., Krishnamurthy, G., Mansour, T., O'Connell, J. (2008). Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796. Antimicrob. Agents Chemother. 52: 3327-3338 [Abstract] [Full Text]  
  • Gozdek, A., Zhukov, I., Polkowska, A., Poznanski, J., Stankiewicz-Drogon, A., Pawlowicz, J. M., Zagorski-Ostoja, W., Borowski, P., Boguszewska-Chachulska, A. M. (2008). NS3 Peptide, a Novel Potent Hepatitis C Virus NS3 Helicase Inhibitor: Its Mechanism of Action and Antiviral Activity in the Replicon System. Antimicrob. Agents Chemother. 52: 393-401 [Abstract] [Full Text]  
  • Zhou, Y., Bartels, D. J., Hanzelka, B. L., Muh, U., Wei, Y., Chu, H.-M., Tigges, A. M., Brennan, D. L., Rao, B. G., Swenson, L., Kwong, A. D., Lin, C. (2008). Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease. Antimicrob. Agents Chemother. 52: 110-120 [Abstract] [Full Text]  
  • Zhou, Y., Muh, U., Hanzelka, B. L., Bartels, D. J., Wei, Y., Rao, B. G., Brennan, D. L., Tigges, A. M., Swenson, L., Kwong, A. D., Lin, C. (2007). Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants: SENSITIVITY TO TELAPREVIR (VX-950) AND INTERFERON {alpha}. J. Biol. Chem. 282: 22619-22628 [Abstract] [Full Text]  
  • Zhu, Q., Oei, Y., Mendel, D. B., Garrett, E. N., Patawaran, M. B., Hollenbach, P. W., Aukerman, S. L., Weiner, A. J. (2006). Novel robust hepatitis C virus mouse efficacy model.. Antimicrob. Agents Chemother. 50: 3260-3268 [Abstract] [Full Text]  
  • Ma, S., Boerner, J. E., TiongYip, C., Weidmann, B., Ryder, N. S., Cooreman, M. P., Lin, K. (2006). NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon.. Antimicrob. Agents Chemother. 50: 2976-2982 [Abstract] [Full Text]  
  • Lin, K., Perni, R. B., Kwong, A. D., Lin, C. (2006). VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells.. Antimicrob. Agents Chemother. 50: 1813-1822 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»